Background Appropriate interpretation of pulmonary function tests (PFTs) involves the
classification of observed values as within/outside the normal range based on a reference …

Two antifibrotic medications (nintedanib and pirfenidone) were recommended
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …

Objectives To identify overall disease course, progression patterns and risk factors
predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis …

Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …

Objective To determine the prognostic value of pulmonary function test (PFT) trends at 1 and
2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Methods …

Objective We provide evidence‐based recommendations regarding screening for interstitial
lung disease (ILD) and the monitoring for ILD progression in people with systemic …

Pulmonary complications in CTD are common and can involve the interstitium, airways,
pleura and pulmonary vasculature. ILD can occur in all CTD (CTD‐ILD), and may vary from …

Objectives To identify the predictive clinical characteristics and establish a prediction model
for the progression of mild interstitial lung disease (ILD) in patients with systemic sclerosis …

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and
is characterized by vascular damage, inflammation and fibrosis of the skin and various …

Systemic sclerosis (SSc) is associated with high mortality owing to internal organ
complications, and lung disease is the leading cause of SSc-associated death. The most …